Literature DB >> 18647623

The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies.

M A Tarnopolsky1.   

Abstract

Mitochondrial cytopathies ultimately lead to a reduction in aerobic energy transduction, depletion of alternative energy stores, increased oxidative stress, apoptosis and necrosis. Specific combinations of nutraceutical compounds can target many of the aforementioned biochemical pathways. Antioxidants combined with cofactors that can bypass specific electron transport chain defects and the provision of alternative energy sources represents a specific targeted strategy. To date, there has been only one randomized double-blind clinical trial using a combination nutraceutial therapy and it showed that the combination of creatine monohydrate, coenzyme Q10, and alpha-lipoic acid reduced lactate and markers of oxidative stress in patients with mitochondrial cytopathies. Future studies need to use larger numbers of patients with well defined clinical and surrogate marker outcomes to clarify the potential role for combination nutraceuticals ("mitochondrial cocktail") as a therapy for mitochondrial cytopathies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18647623     DOI: 10.1016/j.addr.2008.05.001

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  47 in total

Review 1.  The neuro-ophthalmology of mitochondrial disease.

Authors:  J Alexander Fraser; Valérie Biousse; Nancy J Newman
Journal:  Surv Ophthalmol       Date:  2010-05-14       Impact factor: 6.048

2.  Maternal antioxidants prevent β-cell apoptosis and promote formation of dual hormone-expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure.

Authors:  Jennifer E Bruin; Amanda K Woynillowicz; Bart P Hettinga; Mark A Tarnopolsky; Katherine M Morrison; Hertzel C Gerstein; Alison C Holloway
Journal:  J Diabetes       Date:  2012-09       Impact factor: 4.006

Review 3.  Inherited mitochondrial genomic instability and chemical exposures.

Authors:  Sherine S L Chan
Journal:  Toxicology       Date:  2017-07-26       Impact factor: 4.221

Review 4.  Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment.

Authors:  Dmitriy M Niyazov; Stephan G Kahler; Richard E Frye
Journal:  Mol Syndromol       Date:  2016-06-03

Review 5.  Carnitine Palmitoyl Transferase Deficiency in a University Immunology Practice.

Authors:  Kiley Bax; Paul J Isackson; Molly Moore; Julian L Ambrus
Journal:  Curr Rheumatol Rep       Date:  2020-02-14       Impact factor: 4.592

Review 6.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

7.  Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy.

Authors:  Jorge Galino; Montserrat Ruiz; Stéphane Fourcade; Agatha Schlüter; Jone López-Erauskin; Cristina Guilera; Mariona Jove; Alba Naudi; Elena García-Arumí; Antoni L Andreu; Anatoly A Starkov; Reinald Pamplona; Isidre Ferrer; Manuel Portero-Otin; Aurora Pujol
Journal:  Antioxid Redox Signal       Date:  2011-06-08       Impact factor: 8.401

Review 8.  Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems.

Authors:  Adam J Kuszak; Michael Graham Espey; Marni J Falk; Marissa A Holmbeck; Giovanni Manfredi; Gerald S Shadel; Hilary J Vernon; Zarazuela Zolkipli-Cunningham
Journal:  Annu Rev Pathol       Date:  2017-11-03       Impact factor: 23.472

9.  Kearns-Sayre syndrome presenting as isolated growth failure.

Authors:  Conisha Mone Holloman; Lynne A Wolfe; William A Gahl; Cornelius F Boerkoel
Journal:  BMJ Case Rep       Date:  2013-02-18

10.  Beneficial effects of a Q-ter based nutritional mixture on functional performance, mitochondrial function, and oxidative stress in rats.

Authors:  Jinze Xu; Arnold Y Seo; Darya A Vorobyeva; Christy S Carter; Stephen D Anton; Angela M S Lezza; Christiaan Leeuwenburgh
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.